Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 79,191 matching trials from the live ClinicalTrials.gov search.
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2014
U.S. locations
92
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Trial of the Families Moving Forward (FMF) Connect Mobile Health Intervention

NCT04194489
Conditions
Fetal Alcohol Spectrum Disorders
Interventions
FMF Connect
Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, New York
Completed No phase listed Observational Accepts healthy volunteers

Scleroderma Registry

NCT00074568
Conditions
Systemic Sclerosis, Scleroderma
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
18 Years to 70 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2022
U.S. locations
1
States / cities
Houston, Texas
Terminated Not applicable Interventional Results available

The Effect of AposTherapy on Knee Pain

NCT03171168
Conditions
Knee Osteoarthritis, Knee Pain
Interventions
AposTherapy, Traditional Physical Therapy
Device · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Multiple Myeloma
Interventions
Cevostamab, Tocilizumab, Pomalidomide, Daratumumab, Dexamethasone
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
6
States / cities
Duarte, California • Irvine, California • Denver, Colorado + 3 more
Conditions
Chronic Pelvic Pain
Interventions
Compass Health TENS 3000, 3 mode Analog Unit
Device
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 90 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Albany, New York
Conditions
Cancer, Cancer Pain
Interventions
Guided imagery, Virtual reality
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Completed Phase 3 Interventional Results available

Occipital Blocks for Acute Migraine

NCT03526874
Conditions
Chronic Migraine, Headache, Episodic Migraine
Interventions
Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
7 Years to 21 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Low-grade Glioma
Interventions
ReMind iPad app, Healthy SMS texting, In-person cognitive rehabilitation, Telehealth cognitive rehabilitation
Device · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
San Francisco, California
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV Vaccine (GSK3844766A) unadjuvanted low dose, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) low dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted medium dose, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) medium dose adjuvanted with AS01B, RSV Vaccine (GSK3844766A) unadjuvanted high dose, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01E, RSV Vaccine (GSK3844766A) high dose adjuvanted with AS01B, Placebo (Saline solution)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
18
States / cities
Jacksonville, Florida • Miami, Florida • Stockbridge, Georgia + 15 more
Conditions
Advanced Solid Tumor, IDH1 Mutation, Glioma
Interventions
ivosidenib and nivolumab
Drug
Lead sponsor
Jason J. Luke, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Lung Cancer
Interventions
porfimer sodium, bronchoscopy
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Completed Not applicable Interventional Results available

Dalfampridine and Gait in Spinocerebellar Ataxias

NCT01811706
Conditions
Spinocerebellar Ataxias Type 1, Spinocerebellar Ataxias Type 2, Spinocerebellar Ataxias Type 3, Spinocerebellar Ataxias Type 6
Interventions
Dalfampridine, Placebo
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Gainesville, Florida
Active, not recruiting Phase 1 Interventional

Safe Accelerated Venetoclax Escalation in CLL

NCT04843904
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Venetoclax, Obinutuzumab, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Knee Osteoarthritis, Pain, Postoperative
Interventions
Multimodal analgesia including pregabalin, Multimodal analgesia not including pregabalin
Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Great Neck, New York
Conditions
Corneal Ectasia Disorders Including Keratoconus
Interventions
CXL
Drug
Lead sponsor
Rush Eye Associates
Other
Eligibility
10 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Amarillo, Texas
Conditions
Colorectal Cancer
Interventions
ABT-751
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
6
States / cities
Los Angeles, California • Santa Monica, California • Chicago, Illinois + 2 more
Conditions
Suicidal Ideation, Major Depressive Disorder
Interventions
MagVenture TMS Therapy System w/Theta Burst Stimulation, Sham MagVenture TMS Therapy System w/Theta Burst Stimulation
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Recruiting Not applicable Interventional Accepts healthy volunteers

Digital vs. Parent Modeled Toothbrushing

NCT07441148
Conditions
Plaque Reduction
Interventions
MoodBrush Digital Application
Device
Lead sponsor
University of Southern California
Other
Eligibility
3 Years to 6 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Head and Neck Cancer
Interventions
Erlotinib
Drug
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Danville, Pennsylvania
Completed Phase 1Phase 2 Interventional Results available

Sterile Amniotic Fluid Filtrate Epidural Injection.

NCT04537026
Conditions
Lumbar Spinal Stenosis
Interventions
Amniotic Fluid Allograft, Dexamethasone sodium phosphate
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Sickle Cell Disease, Vaso-occlusive Pain Episode in Sickle Cell Disease, Acute Pain
Interventions
Virtual Reality Headset and Hand-Held Controllers, Blindfolding and Noise Cancelling
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Solid Tumors
Interventions
mRNA-4157, Pembrolizumab, SoC Treatment
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Ramucirumab (LY3009806) in Healthy Participants

NCT04495478
Conditions
Healthy
Interventions
Ramucirumab - IV, Placebo - IV, Ramucirumab - SC, Placebo - SC
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Daytona Beach, Florida